Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Dec 26, 2022
TickeronGET DAILY SIGNALS
Centogene's (CNTG, $0.90) loss widens in Q2

Centogene's (CNTG, $0.90) loss widens in Q2

Centogene incurred a net loss of -€11.9m for the second quarter, which was wider by -48% compared to 2Q 2021. On a per-share basis, loss was -€0.44 (vs. - €0.37 loss in the year-ago quarter).

Revenue plunged -78% year-over-year to €11.2m in the quarter, missing analysts’ estimates by 3.1%.

Related Ticker: CNTGF

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies

Industry MedicalSpecialties

Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.50 central target is a fallback objective drawn from public market and technical discussion, not an analyst consensus, because AquaBounty Technologies, Inc. (NASDAQ: AQB) has no credible, current sell-side price targets. With the stock near $0.95, reaching $1.50 would require roughly 58% upside, a very large move for a company that has wound down its core aquaculture operations.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA dropped from Friday's close of $186.64 to $174.06 intraday, down -6.74%, during regular market hours. The slide followed CEO Jensen Huang's admission of an extramarital affair and the board's independent investigation, announced November 8, after reports he was targeted by a suspected Chinese intelligence operative.